Early trial seeks to stall aggressive brain tumors
NCT ID NCT05076513
Summary
This early-stage study is testing whether the drug niraparib can effectively reach brain tumors and slow their growth. It involves 42 adults with newly diagnosed glioblastoma or a specific type of recurrent brain cancer. The trial first checks if the drug gets into the tumor during a short pre-surgery dose; patients showing a good response may then receive longer-term treatment with niraparib, combined with radiation for some.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
Conditions
Explore the condition pages connected to this study.